Xofluza (Baloxavir Marboxil) is a novel anti-influenza virus drug primarily used for the treatment and prevention of influenza A and B virus infections. As a prescription medication, its use must strictly follow medical guidance.
What Are the Precautions for Using Xofluza (Baloxavir Marboxil)?
Eligible Populations and Contraindications
The necessity of administering Xofluza requires careful evaluation, especially for specific populations.
The drug is contraindicated in patients with a history of allergy to any of its components.
Before prescribing, physicians must fully understand the patient’s medical history, allergy history, and current condition.
Medication Warnings for Special Populations
Pediatric Patients
Medication for children weighing less than 20kg requires extra caution; consideration should be given to using other anti-influenza virus drugs.
Studies show that the younger the child, the higher the frequency of low-susceptibility virus strains. Decisions should be made in conjunction with the latest clinical guidelines.
Management of Drug Interactions
Clinical findings indicate that concurrent use with warfarin may prolong prothrombin time. Therefore, when combined use is necessary, close monitoring of the patient’s condition and appropriate preventive measures are required.
Medication Time Windows
Therapeutic use: Should start as soon as possible after symptom onset, no later than 48 hours.
Prophylactic use: Should start within 2 days after exposure to influenza patients; the preventive effect lasts no more than 10 days after administration.
Medication Monitoring for Xofluza (Baloxavir Marboxil)
Efficacy Monitoring Indicators
Clinical efficacy monitoring mainly includes symptom improvement and virus clearance rate.
Research data show that Xofluza can shorten the course of influenza.
It also shows good therapeutic effects in high-risk populations.
During treatment, closely observe changes in the patient’s temperature, respiratory symptoms, and other indicators.
Laboratory Monitoring
Coagulation function: Monitor for bleeding tendencies, such as melena, epistaxis, hematuria, and other symptoms.
Liver function: Regularly test indicators such as ALT and AST.
Hematological parameters: Monitor changes in platelets and other indicators.
Monitoring of Special Populations
Pediatric patient monitoring: Neonates and infants are at risk of vitamin K deficiency, which may lead to bleeding tendencies. Before medication, confirm that the patient has received vitamin K preparation prophylaxis as required.
Geriatric patient monitoring: Elderly patients generally have declining physiological functions. Strengthen clinical observation during medication and adjust the treatment plan in a timely manner.
